ELIL

Direxion Daily LLY Bull 2X Shares

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 66.7%
Negative

Positive
Benzinga
22 days ago
Healthcare Opportunities And Risks Collide For Direxion's Eli Lilly-Focused ELIL, ELIS ETFs
As the largest publicly traded U.S. healthcare enterprise, Eli Lilly & Co. (NYSE:LLY) has historically offered investors a reliable avenue for growth. Indeed, this narrative has been particularly powerful in 2023 and 2024, which saw LLY stock rise from around $360 to approximately $960 in late summer of last year.
Healthcare Opportunities And Risks Collide For Direxion's Eli Lilly-Focused ELIL, ELIS ETFs
Neutral
ETF Trends
1 month ago
Leveraged ETFs: Single-Stock Surge
2025 has so far been a big year for leveraged ETFs. I wrote a research note on leveraged ETFs earlier this year (read more here) where I discussed some trends in the leveraged ETF market.
Leveraged ETFs: Single-Stock Surge
Neutral
ETF Trends
2 months ago
Are More Challenges Ahead for Eli Lilly After Earnings Beat?
Getting stuck in sideways purgatory can leave traders flummoxed. Should they cut bait or ride out the position in hopes that it will eventually trend upwards?
Are More Challenges Ahead for Eli Lilly After Earnings Beat?
Neutral
Zacks Investment Research
6 months ago
Best Leveraged ETFs of Last Week
Wall Street delivered mixed-to-downbeat performance last week thanks to Powell's warning of stagflation, rise of auto stocks on policy hopes, NVIDIA's $5.5B hit on export curb and upbeat retail sales.
Best Leveraged ETFs of Last Week
Neutral
ETF Trends
7 months ago
Direxion Debuts New Single-Stock ETFs for Eli Lilly & Palo Alto
On Wednesday, Direxion expanded its suite of leveraged and inverse ETF products with the launch of four new funds.  Each of the new Direxion ETFs offers leveraged or inverse exposure to a single stock's daily price performance.
Direxion Debuts New Single-Stock ETFs for Eli Lilly & Palo Alto